Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX opened at $0.45 on Tuesday. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The firm has a market cap of $18.57 million, a price-to-earnings ratio of -0.46 and a beta of 1.03. The firm’s 50-day simple moving average is $0.61 and its 200 day simple moving average is $0.56.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CGTX shares. Chardan Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research note on Wednesday, February 26th. HC Wainwright increased their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.30.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.